We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Real-world Evidence of COVID-19 Vaccines Effectiveness

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04981405
Recruitment Status : Terminated (low recruitment, end of COVID-19 pandemic)
First Posted : July 29, 2021
Last Update Posted : July 22, 2022
Sponsor:
Collaborators:
European University at St. Petersburg
Medical Institute named after Berezin Sergey
Information provided by (Responsible Party):
Ivan S Moiseev, St. Petersburg State Pavlov Medical University

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is an observational case-control study to evaluate COVID-19 vaccine effectiveness against hospitalisation with COVID-19 related conditions in St. Petersburg, Russia. Two sets of cases and control will be retrospectively analyzed to compare vaccination proportions and other characteristics to infer vaccine effectiveness from odds ratios. The first set of cases will be extracted from the data on hospitalisation of patients with COVID-19 to First Pavlov State Medical University of Saint-Petersburg hospitals, and controls will be patients hospitalised with other conditions. The second set of cases and controls will be based on patients referred to Medical Institute named after Berezin Sergey for computed tomography. Cases will be patients with positive SARS-CoV-2 status computed tomography confirmed pneumonia or patients referred to hospitalisation, and control will be patients without pneumonia and not referred to hospitalisation.

Condition or disease Intervention/treatment
COVID-19 Pneumonia Biological: COVID-19 Vaccines

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 182 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Real-world Evidence of COVID-19 Vaccine Effectiveness Against COVID-19 Hospitalization: the Case-control Study in St. Petersburg, Russia
Actual Study Start Date : July 16, 2021
Actual Primary Completion Date : July 19, 2022
Actual Study Completion Date : July 19, 2022

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
Patients hospitalised to clinics of First Pavlov State Medical University of Saint - Petersburg
450 cases - patients hospitalised with COVID-19 450 control - patients hospitalised without COVID-19 in the same period (surgical, oncological, cardiological, ophthalmologic, gastroenterological departments)
 Biological: COVID-19 Vaccines
"Gam-COVID-Vac" "EpiVacCorona" "COVIVAC"
Patients referred to Medical Institute named after Berezin Sergey for computed tomography
Cases - patients with pneumonia confirmed after computed tomography. Controls - patients without pneumonia after computed tomography.
 Biological: COVID-19 Vaccines
"Gam-COVID-Vac" "EpiVacCorona" "COVIVAC"


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Effectiveness of full vaccination against hospitalization with COVID-19 pneumonia [ Time Frame: 3 months ]
    Full vaccination effectiveness is calculated based on the odds ratio of vaccination proportions in cases and controls, adjusted for other patient characteristics. Full vaccination status is assigned after two weeks of the second dose for each vaccine separately.


Secondary Outcome Measures :
  1. Effectiveness of partial vaccination against hospitalization with COVID-19 pneumonia [ Time Frame: 3 months ]
    Partial vaccination effectiveness is calculated based on the odds ratio of vaccination proportions in cases and controls, adjusted for other patient characteristics. Partial vaccination status is assigned after two weeks of the first dose for each vaccine separately.

  2. Effectiveness of vaccination against hospitalization with COVID-19 pneumonia in different age groups [ Time Frame: 3 months ]
    Evaluate vaccine effectiveness in different age groups (<20, 20-29, 30-39, 40-49, 50-59, 60-69, >70)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Residents of Saint-Petersburg, Russia
Criteria

Inclusion Criteria:

  • Patients hospitalized to clinics of First Pavlov State Medical University of Saint-Petersburg
  • Patients referred to Medical Institute named after Berezin Sergey for computed tomography
  • Available vaccination status

Exclusion Criteria:

- Refusal to provide information for research purposes at the time of hospitalization or reference to computed tomography

Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04981405


Locations
Layout table for location information
Russian Federation
Mikhail Cherkashin
Saint Petersburg, Saint-Petersburg, Russian Federation, 197022
Oksana Stanevich
Saint Petersburg, Russian Federation, 197022
Sponsors and Collaborators
Ivan S Moiseev
European University at St. Petersburg
Medical Institute named after Berezin Sergey
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Layout table for additonal information
Responsible Party: Ivan S Moiseev, Dr, St. Petersburg State Pavlov Medical University
ClinicalTrials.gov Identifier: NCT04981405    
Other Study ID Numbers: CDRU-003
First Posted: July 29, 2021    Key Record Dates
Last Update Posted: July 22, 2022
Last Verified: July 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
 Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases